<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03499275</url>
  </required_header>
  <id_info>
    <org_study_id>241055</org_study_id>
    <nct_id>NCT03499275</nct_id>
  </id_info>
  <brief_title>Muscle Stimulation in Advanced Idiopathic Pulmonary Fibrosis</brief_title>
  <acronym>MUST-IPF</acronym>
  <official_title>MUscle STimulation in Advanced Idiopathic Pulmonary Fibrosis: a Randomised Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Brompton &amp; Harefield NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kings Clinical Trials Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Royal Brompton &amp; Harefield NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of this study are to determine whether neuromuscular stimulation (NMES) of the
      quadriceps muscle is acceptable to patients with Idiopathic Pulmonary Fibrosis (IPF) and
      staff and whether it can impact clinical and healthcare resource usage outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with IPF who consent to participate in the study will be allocated by chance to use
      'active' or 'sham/placebo' NMES for six weeks. Patients will also complete a home exercise
      programme and receive advice on how to manage breathlessness. Clinical outcomes and trial
      flow after this six week programme and six weeks after patients have stopped using NMES will
      be assessed. After this point, healthcare resource use during the study period will be
      evaluated and interviews involving participants, their carers, and staff about their
      experiences of the study and using or delivering NMES will be conducted.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">March 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a study that comprises:
A parallel group, randomised placebo-controlled, assessor-blinded trial with participants randomised (1:1) to usual care (home based exercise programme) with either placebo or active NMES for six weeks, with a 12 week follow-up.
Qualitative interviews with participants and staff.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Six minute walk test</measure>
    <time_frame>Six weeks</time_frame>
    <description>Exercise capacity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quadriceps maximum voluntary contraction</measure>
    <time_frame>Six weeks and twelve weeks</time_frame>
    <description>Muscle strength</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rectus-femoris cross-sectional area</measure>
    <time_frame>Six weeks and twelve weeks</time_frame>
    <description>Muscle size</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>King's Brief Interstitial Lung Disease questionnaire</measure>
    <time_frame>Six weeks and twelve weeks</time_frame>
    <description>Measure of health-related quality of life that includes three domains (psychological, breathlessness and activities, chest symptoms) and a total score. The score range for each domain and the total score ranges from 0 to 100 with higher scores indicating better health-related quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six minute walk test</measure>
    <time_frame>Twelve weeks</time_frame>
    <description>Exercise capacity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Sham NMES</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham neuromuscular electrical stimulation plus home exercise programme and advice on breathlessness management</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active NMES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neuromuscular electrical stimulation plus home exercise programme and advice on breathlessness management</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active NMES</intervention_name>
    <description>Neuromuscular electrical stimulation to the quadriceps muscle</description>
    <arm_group_label>Active NMES</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham NMES</intervention_name>
    <description>Sham neuromuscular electrical stimulation to the quadriceps muscle</description>
    <arm_group_label>Sham NMES</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Home exercise programme</intervention_name>
    <description>Home exercise programme. Both arms of the trial receive this intervention.</description>
    <arm_group_label>Sham NMES</arm_group_label>
    <arm_group_label>Active NMES</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Breathlessness advice</intervention_name>
    <description>Breathlessness advice. Both arms of the trial receive this intervention.</description>
    <arm_group_label>Sham NMES</arm_group_label>
    <arm_group_label>Active NMES</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of IPF according to international standards.

          -  Severe respiratory disability / breathlessness (Medical Research Council dyspnoea
             score ≥4).

          -  Able to provide written informed consent.

          -  Declined or failed to complete a supervised centre-based pulmonary rehabilitation (PR)
             programme

          -  Quadriceps maximum voluntary contraction &lt;80% predicted.

        Exclusion Criteria:

          -  Cardiac pacemaker.

          -  Co-existing neurological condition.

          -  Change in medication or exacerbation requiring admission in preceding four weeks.

          -  Current regular exerciser (structured supervised training ≥3 times per week within
             last month).

          -  People who have completed PR in the previous six months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William DC Man, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Brompton and Harefield NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claire M Nolan, MSc</last_name>
    <phone>00441895 828851</phone>
    <email>c.nolan@rbht.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Suhani Patel, MSc</last_name>
    <phone>00441895828851</phone>
    <email>s.patel122619@rbht.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Brompton and Harefield NHS Foundation Trust</name>
      <address>
        <city>Harefield</city>
        <state>Middlesex</state>
        <zip>UB9 6JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2018</study_first_submitted>
  <study_first_submitted_qc>April 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2018</study_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neuromuscular electrical stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

